Generic Fotivda Availability
Last updated on Apr 10, 2025.
Fotivda is a brand name of tivozanib, approved by the FDA in the following formulation(s):
FOTIVDA (tivozanib hydrochloride - capsule;oral)
-
Manufacturer: AVEO PHARMS
Approval date: March 10, 2021
Strength(s): EQ 0.89MG BASE [RLD], EQ 1.34MG BASE [RLD]
Is there a generic version of Fotivda available?
No. There is currently no therapeutically equivalent version of Fotivda available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fotivda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Use of tivozanib to treat subjects with refractory cancer
Patent 11,504,365
Issued: November 22, 2022
Inventor(s): Bailey; Michael P. et al.
Assignee(s): AVEO Pharmaceuticals, Inc. (Boston, MA)Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.
Patent expiration dates:
- November 5, 2039✓
- November 5, 2039
-
Quinoline derivatives and quinazoline derivatives having azolyl group
Patent 6,821,987
Issued: November 23, 2004
Inventor(s): Kubo; Kazuo et al.
Assignee(s): Kirin Beer Kabushiki Kaisha (Tokyo-to, JP)An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: ##STR1##
wherein X and Z represent CH or N; Y represents O or S; R.sup.1, R.sup.2, and R.sup.3 represent H, alkoxy or the like; R.sup.4 represents H; R.sup.5, R.sup.6, R.sup.7, and R.sup.8 represent H, halogen, alkoxy or the like; R.sup.9 and R.sup.10 represent H, alkyl or the like; and R.sup.11 represents optionally substituted azolyl.Patent expiration dates:
- April 26, 2025✓✓✓
- April 26, 2025
-
N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxaz- olyl)urea salt in crystalline form
Patent 7,166,722
Issued: January 23, 2007
Inventor(s): Matsunaga; Naoki et al.
Assignee(s): Kirin Beer Kabushiki Kaisha (Tokyo-To, JP)The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl- -3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.
Patent expiration dates:
- November 16, 2028✓✓
- November 16, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 10, 2026 - NEW CHEMICAL ENTITY
More about Fotivda (tivozanib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
